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ABSTRACT 
Posttranslational modifications of histones (so-called epigenetic modifications) play a major 
role in transcriptional control and normal development, and are tightly regulated. Disruption 
of their control is a frequent event in disease. Particularly, the methylation of lysine 27 on 
histone H3 (H3K27), induced by the methylase Enhancer of Zeste homolog 2 (EZH2), 
emerges as a key control of gene expression, and a major regulator of cell physiology. The 
identification of driver mutations in EZH2 has already led to new prognostic and therapeutic 
advances, and new classes of potent and specific inhibitors for EZH2 show promising results 
in preclinical trials. This review examines roles of histone lysine methylases and demetylases 
in cells, and focuses on the recent knowledge and developments about EZH2. 
 
Key-terms: epigenetic, histone methylation, EZH2, cancerology, tumors, apoptosis, cell 
death, inhibitor, stem cells, H3K27 
 
  
 3 
 
Histone modifications and histone code 
Epigenetic has been defined as inheritable changes in gene expression that occur without a 
change in DNA sequence. Key components of epigenetic processes are DNA methylation, 
histone modifications and variants, non-histone chromatin proteins, small interfering RNA 
(siRNA) and micro RNA (miRNA). They induce changes in gene expression in modifying 
accessibility of the eukaryotic transcription machinery to specific genes. In particular, the 
role of histones as active participants in gene regulation has only recently been appreciated.  
Histones were discovered in 1884 by Albrecht Kossel. But until the early 1990s, these 
proteins, which are assembled into nucleosomes, forming beads around which the DNA is 
wrapped, were considered to be relatively inert scaffolding for packaging the genetic 
material. It is now known that histones play also a key-role in gene expression regulation, 
though post-translational modifications of histone (figure 1). In 2000, the concept of a 
‘histone code’ emerged [1]. 
The histones' amino-terminal tails extend away from the central core, and are thus available 
for reversible acetylation, methylation, phosphorylation, ADP-ribosylation, and 
ubiquitination (figure 2). Histone modifications interact with DNA methylation to mark genes 
for silencing or transcription. By reading the combinatorial and/or sequential histone 
modifications that constitute the histone code (table 1), it was thought that it might be 
possible to predict which gene products will be transcribed and thus determine a cell's RNA 
repertoire and ultimately its proteome, just as reading the DNA code allows us to predict the 
encoded protein sequence. However, some gene loci present both histone 3 lysine 4 
trimethylation (H3K4me3), associated with transcriptional activation and histone 3 lysine 27 
trimethylation (H3K27me3), and linked with repression. These bivalent domains are posited 
to be poised for either up- or downregulation and to provide an epigenetic blueprint for 
lineage determination [2], and are usually found in stem cells. 
 These post-translational modifications (PTM) undergone by histones have a profound effect 
on the remodeling of chromatin. Two distinct chromatin states can be distinguished: 
condensed “closed” heterochromatin, and de-condensed “open” euchromatin. The change 
from transcriptionally silenced heterochromatin to gene expression euchromatin is 
mediated by posttranslational modifications of histones and uses of distinct histone variants.  
 
 
 4 
 
Histone lysine methylation 
Histone methylation is an epigenetic mark actively studied in recent years. On about 11 000 
articles referenced in Pubmed since 1964, more than half of them have been published 
during the last four years.  
The most well-characterized histone methylation appears on lysine [3,4]. Histone lysine 
methylation occurs primarily on histone H3 at lysines 4, 9, 14, 18, 23, 27, 36 and 79 and on 
histone H4 at lysine 20 [4–6]. A number of these methylation events have been linked to 
transcriptional regulation, including those at H3 lysines 4, 36 and 79 (associated with active 
transcription) and those at H3 lysines 9 and 27 (associated with gene repression and 
heterochromatin formation) [3,7]. Unlike acetylation and phosphorylation, which in addition 
to recruit proteins to chromatin can also directly affect chromatin structure by altering the 
histone charge, lysine methylation does not alter the charge of the residue and is therefore 
thought to primarily modulate chromatin structure through the recruitment of distinct 
reader proteins that possess the ability to facilitate transcriptional activation or repression 
[3,4,6,8].  
Lysine residues can be modified with up to three methyl groups (mono-, di- and 
trimethylation) on the epsilon amine of the side-chain (figure 3). Importantly, reader 
domains can distinguish between the different methyl states producing distinct functional 
outcomes [3,4,6,8]. These observations demonstrate the complexity and fine level of control 
that lysine methylation contributes to chromatin function and transcriptional regulation.   
Among activation marks, trimethylation at lysine 4 of histone H3 (H3K4me3) is the 
prominent methyllysine species at active promoter regions  [9–13]. This mark plays a major 
role in transcription initiation, notably in recruiting the general transcription factors, or in 
mediating interactions with RNA polymerase associated proteins [6].  H3K36 methylation, 
meanwhile, primarily exists with the lower methylation states (H3K36me1 and -me2) 
present near 5′ regions and higher methylation states (H3K36me2 and -me3) at the 3′ ends 
of genes [11,14]. The role of H3K36 methylation is also quite diverse and has been shown to 
be involved in numerous functions including transcription, mRNA splicing, DNA replication 
and DNA repair [15,16]. Its function that has been most well defined is its role in 
transcription elongation. Another modification found in gene bodies is methylation of 
H3K79, however, unlike H3K36 methylation, its role in actively transcribed genes is less clear. 
It may act as a protection from silencing [6]. 
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At opposite, histone H3 lysine 9 methylation (H3K9) has been correlated with 
heterochromatin formation and transcriptional repression, making the methylation state of 
lysine 9 an interesting marker of transcriptional activity. H3K9me3 binds heterochromatin 
protein 1 (HP1) to constitutive heterochromatin [17]. HP1 is responsible for transcriptional 
repression and the actual formation and maintenance of heterochromatin. H3K9me2 is a 
characteristic mark of the inactivated X chromosome (Xi) [18,19].  H3K9 methylation is also 
involved in cell reprogramming, or cancer. H3K27 methylation is also another epigenetic 
repressive mark, which plays a major role in a plethora of cellular processes, such as stem 
cell renewal, cell fate, reprogramming, cancer, inflammation. 
 
Histone arginine methylation 
As lysine, arginine on histone can also be methylated. The addition of one or two methyl 
groups on arginine residues results in three different methylation states: monomethylated, 
asymmetrically dimethylated or symmetrically dimethylated arginine. The methyl groups are 
deposited by protein arginine methyltransferases (PRMTs). Histone arginine methylation 
associates with both active and repressed chromatin states depending on the residue 
involved and the status of methylation [20]. This process is involved in several cellular 
processes such as transcription, RNA processing, signal transduction and DNA repair. 
Besides, it is now clear that there is cross-talk between arginine and lysine methylation: this 
has been termed “arginine/lysine-methyl/methyl switch” [21,22] 
 
 
Histone methyltransferases and demethylases 
There are currently more than 60 predicted lysine methyltransferases and 30 predicted 
lysine demethylases in the human genome [23–25].  
Histone methyltransferase (HMT) activity towards lysine (and arginine) residues is found in a 
family of enzymes with a conserved catalytic domain called SET (Suppressor of variegation, 
Enhancer of Zeste, Trithorax). The human genome encodes 49 SET domain-containing 
proteins and the histone lysine methyltransferase DOT1L, which does not contain a SET 
domain (table 2). The importance of HMTs for embryonic development has been 
demonstrated in numerous mouse knockout studies [26]. In addition, misregulation of HMTs 
has been linked to diseases or cancer aggressiveness. In particular, the Polycomb group 
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transcriptional repressor EZH2 (methylase of H3K27), is overexpressed in many different 
types of cancer [27], and has been proposed as a molecular marker of some cancer 
progression and metastasis [28–33]. 
In 2004, the first histone demethylase (HDM) has been discovered, and called LSD1 (lysine-
specific demethylase 1). Since, more than 20 demethylases have been identified and 
characterized (table 3). They belong to either the LSD family or the JmjC family, 
demonstrating the reversibility of all methylation states at almost all major histone lysine 
methylation sites (table 3). The identification of these histone demethylases (HDMs) has 
completely changed our initial view of histone methylation as a permanent, heritable mark 
[34]. The presence of both histone methyltransferases and demethylases in the same 
complexes permits modifying of chromatin marks and subsequently switching of 
transcriptional states from silenced to activated status or vice-versa. Thus, a tight regulation 
of the expression, activity and recruitment of HMTs and HDMs is necessary. A deregulation 
of their activity or expression might modify the transcriptional balance, and lead to 
inappropriate gene expression programs that in turn could induce human disease (table 1 in 
supplementary material). In particular, the histone methylase EZH2 plays a major role in cell 
fate and cancer development, and appear now as a promising target for treat some diseases.  
 
 
Role of the lysine methyltransferase EZH2  
The methyltransferase Polycomb Group (PcG) protein Enhancer of zeste homolog 2 (EZH2), 
also called KMT6, is the catalytic subunit of the Polycomb Repressor Complex 2 (PRC2). Its C-
terminal SET domain exhibits methyltransferase activity, leading to repress gene 
transcription by silencing target genes through methylation of histone H3 on lysine 27 
(H3K27me3) [35]. In addition to methylation of H3K27, EZH2 has been shown to methylate 
cellular proteins and act as a co-activator of steroid hormone receptors [36]. This function is 
hypothesized to be independent of PRC2 and potentially induced by phosphorylation of 
EZH2 [36,37]. Besides its ability of methylate H3K27, EZH2 has recently been described to 
methylate lysine 120 of histone H2B which competes with ubiquitination on this site [38].  
EZH2 is post-translationnaly regulate by O-linked N-acetylglucosamine (GlcNAc) transferase 
(OGT)-mediated O-GlcNAcylation at S75, which stabilizes EZH2 and hence facilitates the 
formation of H3K27me3 [39].  
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Unlike other SET domains, the methylase EZH2 is inactive on its own for histone substrates. 
To be functional, EZH2 need to  form the PRC2 complex (figure 4) by interacting with other 
partners, including embryonic ectoderm development (EED), suppressor of zeste 12 
homologue (SUZ12), and RBAP48/RBBP4 [40–43]. Collectively, these proteins regulate vital 
cellular processes, such as differentiation, cell identity, stem-cell plasticity, and proliferation 
[44–46]. As a result, aberrations in any PRC2 component can have powerful physiologic 
consequences on the cell.  
 
EZH2, stem cells and reprogramming 
EZH2 plays a central role in stem cells. Recent report showed that Ezh2 is important for 
establishing ES cell lines from blastocysts [47–49]. Additionally, Ezh2 is required for efficient 
somatic cell reprogramming by cell fusion and nuclear transfer [49,50]. Ezh2 is abundantly 
expressed in iPS cells (at a similar level as in ES cells), and Ezh2 knockdown severely impaired 
iPS cell generation. Proper differentiation of iPS cells and reprogrammation require, thus, 
Ezh2 [51]. However, once pluripotency is established, Ezh2 knockdown leaves the 
pluripotent phenotype of iPS cells unaffected [52]. All this indicates that Ezh2 is critical for 
induction of pluripotency, but once pluripotency is established, Ezh2 is not required 
anymore. The mechanism of EZH2 in reprogramming is still poorly known, but it has been 
recently found that Ezh2 impacts on iPS cell generation at least in part through repression of 
the CDK inhibitor Ink4a/Arf, which represents a major roadblock for iPS cell generation [52]. 
Furthermore, c-Myc, one of the iPS cell inducing factors, was recently shown to directly 
regulate the Ezh2 expression and to be required for maintaining high Ezh2 expression in ES 
cells [53].  
The role of EZH2 in reprogramming is, however, unclear. Indeed, in a recent paper[54], 
Fragola et al. generated iPS cells from MEF with a conditional Ezh2 knockout allele for the 
deletion of the catalytic Ezh2 SET domain [54]. Ezh2-deficient iPS cells, obtained using a cell-
permeable TAT-Cre recombinase, exhibited a global loss of H3K27me3, and presented a 
typical iPS cell phenotype, including ES cell-like morphology, growth, and differentiation 
potential. This result on Ezh2-deficient iPS cells contrasts other papers which showed 
essential role of EZh2 in reprogramming [51,52]. It might be explain by used methodology, in 
that Ezh2 inactivation could have occurred after reprogramming. 
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EZH2 and cell fate 
Enhancer of zeste homolog 2 also regulates expression of tissue-specific genes involved in 
cellular differentiation and developmental programs [35,55–58]. It is involved in 
differenciation of embroyonic and adult stem cells into several cell lineages (myogenesis, 
adipogenesis, osteogenesis, neurogenesis, hematopoiesis, lymphopoiesis, epidermal 
differenciation and hepatogenesis) [59]. 
For instance, EZH2 was clearly shown to act as a negative regulator of skeletal muscle 
differentiation favoring the proliferation of myogenic precursors [60–62]. This function 
results from an EZH2-dependent direct repression of genes related to myogenic 
differentiation [60] through the H3K27me3 mark deposition on the promoters of myogenic 
genes [60,63]. EZh2 is expressed early in the myotomal compartment of developing somites 
and in proliferation satellite cells and is down-regulated in terminally differentiated muscle 
cells [60]. In skeletal muscle progenitors, EZH2 is, thus, highly expressed and prevents an 
unscheduled differentiation by repressing muscle-specific gene expression. During the 
course of their differentiation, EZH2 is downregulated, favoring the expression of muscle 
specific genes, such as muscle creatine kinase (mCK), myogenin (MyoG), myh, or MyoD 
[64,65]. Furthermore, the key-role of EZH2 in control of self-renewal and safeguard of the 
transcriptional identity of skeletal muscle stem cells has been shown using mice with 
conditional ablation of Ezh2 in satellite cells. These mice have reduced muscle mass and fail 
to appropriately regenerate. These defects were associated with derepression of genes 
expressed in nonmuscle cell lineages [66]. Besides, in humans, abnormal expression of Ezh2 
is observed in the muscular disorder Duchenne muscular dystrophy [67]. 
EZH2 was also found to be involved in commitment of mesenchymal stem cells towards 
osteoblast lineage [68]. Suppression of Ezh2 activity promotes differenciation of human 
mesenchymal stem cells into osteoblasts. The mechanism might be linked to Runx2 
regulation since a striking decrease in Ezh2 mRNA levels has been found to be correlated to a 
increased Runx2 binding, suggesting that the transcription of Ezh2 is potentially negatively 
regulated by Runx2 [69]. At contrary, deletion of Ezh2 inhibits adipogenesis, by eliminating 
H3K27me3 on Wnt promoters and derepressing Wnt expression, which leads to activation of 
Wnt/b-catenin signaling [70]. These data show that Ezh2 facilitates adipogenesis whereas it 
suppresses osteogenesis. 
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EZH2 and immune system 
EZH2 plays also a role in immune system, for both T and B cell development. Ezh2 is most 
abundant at sites of embryonic lymphopoiesis, such as fetal liver and thymus [71].  
In B cell progenitors, Ezh2 expression is downregulated during differenciation. It is the 
highest in pro-B cells and very low in mature recirculating B cells (Su et al., 2002). Up-
regulation of Ezh2 in proliferating human germinal center B cells (centroblasts) [72] and 
mitogen-stimulated lymphocytes [73] suggested an important role for this histone methylase 
in B cell division and activation. This is further supported by the association of EZH2 with 
Vav, one of the key regulators of the receptor-mediated signaling in lymphocytes [74]. But 
the major proof of a critical role for Ezh2 in early B cell development and rearrangement of 
the immunoglobulin heavy chain gene (Igh) has been established, in 2002, using Cre-
mediated conditional mutagenesis. Ezh2 deficiency leads to diminished generation of pre-B 
cells and immature B cells in the bone marrow. Defective B cell development cannot be 
restored by the presence of the wild-type cells in the mixed bone marrow chimeras. The 
requirement for Ezh2 is development stage−specific: Ezh2  is a key regulator of histone H3 
methylation in early B cell progenitors [75].  
EZH2 is a master regulator of the germinal center (GC) B-cell phenotype [76]. It represses 
genes involved in proliferation checkpoints (e.g. CDKN1A) and in exit from the GC and 
terminal differentiation (e.g. IRF4 and PRDM1). This function is aberrantly reinforced by 
mutant EZH2Y146N lymphoma disease alleles [76]. EZH2 also established bivalent chromatin 
domains at key regulatory loci to transiently suppress GC B-cell differentiation. Beside, EZH2 
cooperates with BCL2 to generate GC derived lymphomas [76]. 
A recent study also established a functional link between this histone methyltransferase 
EZH2 and transcriptional regulation of lineage-specifying genes in terminally differentiated 
CD4(+) T cells. EZH2 inactivation specifically enhanced T helper 1 (Th1) and Th2 cell 
differentiation and plasticity. Ezh2 directly bounds Tbx21 and Gata3 genes, leading to 
substantial trimethylation at lysine 27 of histone 3 (H3K27me3) at these locus, thereby 
facilitating correct expression of these primordial genes in differentiating Th1 and Th2 cells. 
Additionally, Ezh2 deficiency leads to spontaneous generation of a small IFN-γ and Th2 
cytokine-producing populations in non-polarizing cultures, and under these conditions, IFN-γ 
expression was largely dependent on increased expression of the transcription factor 
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Eomesodermin. Besides, in vivo, in a model of allergic asthma,  Ezh2   loss results in 
exacerbated pathology with a progressive accumulation of memory phenotype Th2 cells 
[77]. 
 
EZH2 and cancer 
Among EZH2 roles, its implication in cancer is the most studied: more than 70% of articles 
referenced in Pubmed for “Ezh2” term, are related to cancer. Alterations in EZH2 were first 
discovered in breast and prostate cancer, where amplification and overexpression first 
implied it may function as an oncogene [28,31]. Since, increasing evidence demonstrates 
that EZH2 is not only aberrantly expressed in several types of human cancers, but often 
behaves as a molecular biomarker of poor prognosis [27,28,31,78–84]. The role of EZH2 in 
cancer development was initially validated both in vitro and in vivo, with EZH2 
overexpression proving sufficient to drive proliferation in cancer cells and transform primary 
fibroblasts [27,85].  
 
Overexpression of EZH2 has now been found in a number of human cancers, such as 
prostate cancers, gastric cancers, breast cancer, renal cancer, colorectal cancer, non small 
cell lung cancer, squamous cell carcinomas, urothelial carcinomas in addition to synovial 
sarcomas, chondrosarcoma, lymphomas and melanomas [31,86–91]. EZH2 expression is 
correlated with aggressiveness, metastasis, and poor prognosis in most of these cancers. 
Elevated expression of EZH2 has, also, been identified as a marker for breast cancer initiating 
cells, possibly reflecting its role in maintaining “stemness” [31,92].  
In addition, several mutations, located the most often in SET domain leading to increased 
trimethylation efficiency, have been associated to cancers (table 4) [93–98]. Recurrent 
mutations of EZH2 have been found in germinal center B-cell like diffuse large B-cell 
lymphoma, follicular lymphoma, and melanoma [99]. The mutated residues alter the 
substrate specificity of EZH2 and facilitate the conversion from a dimethylated to a 
trimethylated state, thus resulting in significantly elevated global H3K27me3 levels [93,98]. 
The most frequent identified mutation appears on Y641 (mutations Y/F, Y/N, Y/H, Y/C)  
[98,100,101]. Another mutation has been identify (A677G and A687V) though these mutants 
are less prevalent in [93,102]. 
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Together this data suggests a causative role for elevated catalytic activity of EZH2 in the 
development of cancer. The functional consequence of increased EZH2 (either by 
overexpression or mutations) in cancer tissues includes the silencing of genes that promote 
differentiation and restrain proliferation.   
Nonetheless, a high expression of EZH2 and trimethylation of histone H3 at lysine 27 were 
sometimes associated with improvements in survival. Thus, increased EZH2 expression is 
correlated to better overall survival in diffuse large B-cell lymphoma and lung cancer 
[103,104]. In the same way, a recent report showed that EZH2 serves as a tumor suppressor 
in myelodysplastic syndromes, which was evidenced by EZH2 deletions, missense and 
frameshift mutations [105].  Besides, enhanced trimethylation of H3K27me3 has been 
correlated with longer overall survival and better prognosis in non-small cell lung cancer, 
breast, ovarian and pancreatic cancers [106,107]. 
 
Mechanistically, EZH2 is usually believed to function predominately as a transcriptional 
repressor that silences an array of target genes, including more than 200 tumor suppressors 
[88,108].  EZH2 is identified as a downstream mediator of the retinoblastoma protein (pRB) 
pathway-E2F pathway which controls multiple key cell-cycle regulators during cell 
proliferation in normal and cancer cells [27]. Additionally, EZH2 represses the p16, p19 and 
p15 directly or indirectly which activates the cyclin D-CDK4/6 complex and promotes 
progression through G1 phase and cell proliferation [109,110]. Furthermore, enforced 
expression of EZH2 increases cancer cell proliferation, epithelial-mesenchymal transition, 
metastatic spreading and other oncogenic properties, whereas its depletion inhibited cell 
proliferation, migration and invasion and induced cell apoptosis and senescence both in vitro 
and in vivo [87,111,112]. Besides, EZH2 could cause a rise in cell migration and invasion in 
cancer cells by regulating E-cadherin and MMP [113]. Increasing evidence also suggests that 
aberrant overexpression of EZH2 could contribute to acquired chemotherapeutic resistance 
in multiple cancers [114–116]. 
In addition to its role as a transcriptional repressor, several studies have shown that EZH2 
may also function in target gene activation [36,117,118]. Recently, Xu et al reported that 
EZH2 plays an important role in castration-resistant prostate cancer, and its oncogenic 
function does not depend on silencing but rather on transcriptional induction of its target 
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genes [36]. Many of these genes were downregulated upon EZH2 knockdown, suggesting 
that the role of EZH2 as an activator was independent of the PRC2 complex. This function is 
hypothesized to be induced by phosphorylation of EZH2 [36,37]. 
 
 
Antagonistic relationship between PRC2 and SWI/SNF 
Accumulating evidence has suggested that SWI/SNF (SWitch/Sucrose NonFermentable)  
chromatin-remodeling complex oppose epigenetic silencing by PcG proteins, and functions 
as a tumor suppressor in some cancers. This SWI/SNF complex is a multi-subunit chromatin 
remodeling complex that uses the energy of ATP hydrolysis to reposition nucleosomes, 
thereby regulating access to the DNA and modulating transcription and DNA 
replication/repair [119]. 
The activity of SWI/SNF complex can be counteracted by PcG proteins [120,121]. This 
antagonistic relationship between SWI/SNF components and PcG proteins were first 
uncovered via genetic studies in Drosophila. In 1988, mutations in core components of the 
SWI/SNF complex were found to suppress defects in body segment identity conferred by 
mutations in PcG proteins [122]. Latter, in 90’s year, it was discovered that the SWI/SNF 
complex promotes Hox gene activation during embryogenesis, while PcG proteins maintain 
their repression [123,124]. SWI/SNF is also capable of displacing PcG proteins from the 
INK4a/ARF locus [125]. 
Furthermore, there seems to be a balanced function between SWI/SNF and PcG. 
Accumulating evidence raises the possibility that the antagonistic relationship between 
these two complexes plays important roles in preventing tumor formation in mammals. 
Intriguingly, while PcG proteins are frequently overexpressed in cancers, specific inactivating 
mutations of SWI/SNF complex have been identified in several human cancers [126]. The 
most compelling case has been that of SMARCB1 (SNF5), which was discovered to be 
homozygously inactivated in nearly all rhabdoid tumors (a rare pediatric malignancy) [127]. 
Interestingly, SMARCB1-heterozygous mice develop sarcomas that closely resemble human 
rhabdoid tumors [128]. Tumorigenesis can be completely suppressed by tissue-specific 
codeletion of EZH2, suggesting an antagonistic interaction between PRC2 and SWI/SNF 
[129]. 
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EZH2 inhibitors 
As described above, most findings have established that EZH2 functions as an important 
oncogenic biomarker for cancer initiation and progression, thus leading to the hypothesis 
that blocking EZH2 expression/activity and its downstream signaling cascade may represent 
a promising strategy for novel anticancer treatment.  That’s why several groups have 
developed small-molecule inhibitors of EZH2 [130]. Over the past few years, several potent 
inhibitors of EZH2, with various selectivities, have been discovered and demonstrated 
promising preclinical results (figure 5, table 5). 
 
DZNep as an indirect inhibitor 
The first EZH2 inhibitor which was described is a cyclopentanyl analog of 3-deazaadenosine, 
called 3-Deazaneplanocin A (DZNep). It is a cyclopentanyl analog of 3-deazaadenosine that 
potently inhibits the activity of S-adenosylhomocysteine hydrolase (SAH), resulting in cellular 
accumulation of (SAH) which in turn represses the S-adenosyl-L-methionine-dependent 
histone lysine methyltransferase activities [143] (figure 5). Initially studied for its antiviral 
proprieties, recent findings indicate that DZNep is a chromatin-remodeling compound that 
induces degradation of cellular PRC2 proteins including EZH2 and concomitant removal of 
H3K27me3 mark [79,132]. 
Disruption of EZH2 by DZNep leads to the reactivation of the epigenetically silenced targets. 
This induces apoptosis, inhibits cell invasion and enhances chemotherapeutic sensitivity in 
tumoral cells, but not in normal and untransformed cells at tumor-inhibiting doses [79]. As 
DZNep has minimal toxicity in vivo [144], it may be a promising drug candidate for anti-
cancer treatment. That’s why, it has been widely examined as a possible epigenetic 
therapeutic agent for the treatment of various cancers, including lung cancer [145], gastric 
cancer [146], myeloma [133], acute myeloid leukemia [132], lymphoma [147], but also 
chondrosarcoma [91]. DZNep-induced inhibition of EZH2 dramatically diminished the 
number and self-renewal capacity of cancer cells with tumor-initiating properties and 
significantly decreased tumor xenograft growth and improved survival [134,148]. 
DZNep selectively induced apoptosis in cancer cells but not in normal cells by preferential 
reactivation of genes repressed by PRC2 including the apoptosis effector FBOX32 [79]. EZH2 
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depletion induced not only cell cycle arrest and apoptosis, but also cell senescence. EZH2 
decrease triggered simultaneous remarkable gains of two senescence-associated regulators 
p16 and p21. These data suggest that DZNep exerts its anticancer roles partially through 
inducing cell apoptosis and senescence and inhibiting cell proliferation [149]. Interestingly, 
DZNep also reduces tumoral cell migration and invasion, in part through upregulating E-
cadherin [150]. 
These findings suggested DZNep may be a promising therapeutic agent for cancer treatment 
through multiple mechanisms. Besides its antitumoral role, DZNep has been reported to 
modulate allogeneic T cell responses and may represent a novel therapeutic approach for 
treatment of graft versus host disease [151]. DZNep also promotes erythroid differentiation 
of K562 cells, presumably through a mechanism that is not directly related to EZH2 inhibition  
[152], suggesting that this inhibitor may also be exploited for therapeutic applications for 
hematological diseases, including anemia. 
 
SAM-competitive inhibitor 
Because DZNep is not totally specific to EZH2, significant efforts have been made over the 
past few years to obtain compounds that are potent and highly selective for EZH2 (table 6) 
[99,138,140,141,153]. To identify inhibitors of EZH2 methyltransferase activity, high-
throughput biochemical screening experiments have been performed. Although the 
structure of the EZH2 active site has not yet been determined, the conserved SET domain 
architecture predicts two essential binding pockets: one for the SAM methyl donor and 
another for the Lys27 substrate. Because more than 50 SET domain proteins have been 
identified in humans thus far, the selectivity of the inhibitors is crucial for minimizing off-
target effects [154]. From the end of 2012, several SAM-competitive inhibitors were 
announced with promising preclinical results [153] (figure 5, table 6). 
The compound EPZ005687 has a Ki value of 24 nmol/L and is over 500-fold more selective for 
EZH2 versus 15 other PMTs and 50-fold more selective for EZH2 versus the closely related 
enzyme EZH1 [138]. Interestingly, EPZ005687 can also inhibit H3K27 methylation induced by 
the EZH2 mutants Y646 and A682, and it has been shown to selectively kill lymphoma cells 
that are heterozygous for one of these EZH2 mutations, with minimal effect on the 
proliferation of wild-type cells [138]. Another EZH2 inhibitor developed by Epizyme Inc. is 
EPZ-6438 (also called E7438). It shares similar in vitro properties (i.e. mechanism of action, 
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specificity, and cellular activity) as EPZ005687, but it demonstrates significantly improved 
pharmacokinetic properties, including good oral bioavailability in animals.  Interestingly, oral 
dosing of EPZ-6438 leads to potent in vivo target inhibition and antitumor activity in a 
SMARCB1-deleted malignant rhabdoid tumor xenograft model (21). The ability of EPZ-6438 
to reduce global H3K27Me3 levels was further demonstrated in several other human 
lymphoma cell lines, including lines expressing either wild-type or mutant EZH2. This 
compound is currently under study in a phase 1/2 trial as a single agent in subjects with 
advanced solid tumors or with B cell lymphomas. The primary goal of the phase 1 trial is to 
establish the safety and define the maximal tolerated dose of the drug.  
EI1, another inhibitor of EZH2, was developed by Novartis [140] and shows very good 
selectivity with a low Ki value (approximately 13 nmol/L). Loss of the H3K27 methylation 
function and activation of PRC2 target genes have been observed in EI1-treated cells. EI1 is 
equally active against both wild type and the Y646 mutant form of EZH2, and the inhibition 
of the EZH2 Y646 mutant in B-cell lymphomas decreases the H3K27 methylation level 
genome-wide and activates PRC2 target genes, leading to decreased proliferation, cell cycle 
arrest, and apoptosis [140]. 
Another EZH2 inhibitor is GSK126 (developed by GlaxoSmithKline), which has a Ki of 0.5–3 
nmol/L [99]. The selectivity of GSK126 for EZH2 is more than 1000-fold higher than its 
selectivity for 20 other human methyltransferases containing SET or non-SET domains, and it 
is over 150-fold more selective for EZH2 than for EZH1. McCabe et al. showed that the 
compound GSK126 decreased global methylation at H3K27 and reactivated silenced PRC2 
target genes in EZH2-mutant diffuse large B-cell lymphoma (DLBCL) cell lines [99]. 
Furthermore, this compound effectively inhibited the proliferation of the EZH2-mutant 
DLBCL cells, and suppressed tumor growth in a mouse xenograft model. 
UNC1999, an analogue of GSK126, is the first orally bioavailable inhibitor that has high in 
vitro potency against wild type and mutant EZH2 over a broad range of epigenetic and non-
epigenetic targets. As GSK126, UNC1999 potently reduced H3K27me3 levels in cells (IC50<50 
nmol/L) and selectively killed DLBCL cell lines harboring the Y646N mutation [141]. However, 
UNC1999 shows less selectivity for EZH1 than the inhibitors mentioned above.  
 
Stabilized α-helix of EZH2 (SAH-EZH2) 
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Most recently, Kim et al. developed a peptide called stabilized α-helix of EZH2 (SAH-EZH2), 
which inhibits EZH2 inhibition by a different mechanism from previous inhibitors [142]. SAH-
EZH2 selectively disrupts the contact between EZH2 and EED, another subunit in the PRC2 
complex, whereas the other EZH2 inhibitors target the HMT catalytic domain (figure 5). As in 
the case of GSK126, SAH-EZH2 decreases the H3K27 trimethylation level, resulting in growth 
arrest of PRC2-dependent MLL-AF9 leukemia cells (table 6). 
 
 
Future perspective 
Due to frequent activation of EZH2 in cancers, these new targeted therapies hold exciting 
promise in the clinic. Indeed, as discusses above, several reports have shown that genetic 
silencing and pharmacologic inhibition of EZH2 induced cell apoptosis, inhibited cell invasion 
and tumor angiogenesis, ultimately suppressed cancer growth and progression [155,156]. 
More importantly, given the advantages of specific chemical compounds including 
convenient to use and reversible nature of epigenetic modifications behind carcinogenesis, 
administration of small molecules targeting EZH2 seems to be a plausible and appealing way 
as a novel anti-cancer strategy [157]. However, the down-regulation of the EZH2 causes the 
hepatocytes to become more susceptible to lipid accumulation and inflammation. 
Significantly, from a translational point of view, because EZH2 inhibitors are potential and 
promising drugs useful in the treatment of various types of cancer, the patients who will be 
eventually treated with them should be monitored for the induction of non-alcoholic fatty 
liver disease (NAFLD) as a potential side effect [158]. 
 
Executive summary 
- Histone modifications and histone code: Post-translational modifications of histone play a 
major role in transcriptional control and normal development, and are tightly regulated 
(histone code).  
-  Role of the lysine methyltransferase EZH2:  
* H3K27 methylation is a major epigenetic mark, related to gene silencing, and its control by 
HMTs (EZH2) and HDMs (JMJD3 and UTX) is a major regulator of cell physiology 
(reprogrammation, cell differentiation, immune system, cancers…). 
* EZH2 is overexpressed or mutated in numerous types of cancers. 
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- EZH2 inhibitors: EZH2 inhibitors are promising anticancer drugs 
 
Defined key-terms 
1) A current search of the PubMed database for the term ‘epigenetic’ returns more 
than 33 000 papers, with about half of them published during the past 4 years, 
marking an explosion of research efforts on this topic. Striking is the diversity of 
biological processes that are described in these articles, including fundamental 
aspects of development, cell fate or reprogramming in diverse organisms, as well as 
basic mechanisms of transcriptional control or DNA damage repair. Thus, epigenetic, 
through the modulation of genetic information, plays roles in fundamental life 
processes, such as cell proliferation, cell development, cell fate, or decision between 
cell survival and cell death.  
2) EZH2 (Enhancer of Zeste Drosophila Homolog 2) was initially cloned in 1996. This 
genes located on human chromosome 21 encodes a histone methyltransferase and 
constitutes the catalytic component of the polycomb repressive complex-2 (PRC2). 
EZH2 specifically methylates the histone H3 at lysine-27 (H3K27). It plays a major role 
in a plethora of biological processes, including development, cell fate or 
reprogramming, as well as regulation of immune system or cancers. 
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Figures  
 
 
 
 
Figure 1: Schema of nucleosome organization 
The fundamental DNA packing unit is known as a nucleosome. Each nucleosome is about 
11nm in diameter. The DNA double helix wraps around a central core of eight histone 
protein molecules (an octamer containing 2 H2A, 2 H2B, 2 H3 and 2 H4) to form a single 
nucleosome. The N-terminal “tail” of these histones can undergo post-translational 
modifications (acetylation, methylation or phosphorylation). 
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Figure 2: Schematic representation of major histone modifications 
Histone modifications mainly occur on the N-terminal tails of histones but also on the C-
terminal tails and globular domains. The major modifications shown include acetylation (A), 
methylation (M), phosphorylation (P) and ubiquitination (U).  
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Figure 3: Methyl group transfer reaction on lysine 
The lysine amino group of the substrate histone polypeptide engages in a SN2 reaction with 
the activated co-factor S-adenosyl-L-methionine (SAM), resulting in the formation of an N-
methylated lysine and S-adenosyl-L-homocysteine (SAH). 
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Figure 4: Schematic representation of PRC2 complex.  
(A) Domain organizations of each subunit in the human PRC2 complex.  
Domain “1”, binding region for PHF1 in human cells; domain “2”, binding region for SUZ12; 
CXC, cysteine-rich domain; SANT, domain that allows chromatin remodeling protein to 
interact with histones; SET, catalytic domain of EZH2; VEFS, VRN2-EMF2-FIS2-SUZ12 domain; 
WD, WD-40 domain; WDB, WD-40 binding domain; Zn, Zn-finger region.  
(B) The subunits of human PRC2 complexes, their interactions, and shematic function of 
PRC2 are shown.  
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Figure 5: Modes of inhibition of PRC2. 
Three types of inhibitors are indicated: DZNep as an SAH hydrolase inhibitor, SAM 
competitive inhibitors, and SAH-EZH2 peptides as disrupters of the contact between EZH2 
and EED. 
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Tables 
Table 1: The histone code.1 
 
 Methylation 
Acetylation Ubiquitination 
 
Mono-methylation di-methylation tri-methylation 
H2AK119 - - - - repression 
H2BK5 activation - repression - - 
H3K4 activation activation activation - - 
H3K9 activation repression repression activation - 
H3K14 - - - activation - 
H3K18 - - - activation - 
H3K27 activation repression repression activation - 
H3K36 repression activation activation - - 
H3K56 - - - activation - 
H3K79 activation activation 
activation 
repression 
- - 
H4K12 - - - activation - 
H4K20 activation 
 
repression - - 
  
                                                          
1 For each post-translational modification, the known functional association on gene 
transcription is shown. By reading the combinatorial and/or sequential histone modifications 
that constitute the histone code, it may be possible to predict which gene products will be 
transcribed. However, this code is controversial, since some gene loci present marks both 
associated with transcriptional activation and linked with repression. These bivalent domains 
are posited to be poised for either up- or downregulation and to provide an epigenetic 
blueprint for lineage determination, and are usually found in stem cells. 
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Table 2: Histone target substrates and domain structure of histone lysine 
methyltransferases. 2 
                                                          
2 For each protein, the official name as well as the most commonly used synonyms, the 
histone target substrates and domain structure are provided.  
SET: Suppressor of variegation, Enhancer of Zeste, Trithorax domain; pre/post-SET: cysteine-
rich motifs found adjacent to a subset of SET domains; PHD: plant homeodomain zinc finger; 
ANK: ankyrin repeats; AT hook: A/T DNA binding motif; C2H2 Znf: C2H2-type zinc finger; 
HMG: high mobility group; SANT: SWI3, ADA2, N-CoR and TFIIIB DNA-binding domain; CxxC: 
CxxC zinc finger; MBD: methyl CpG binding domain.  
 
 Synonyms Protein structure Histone substrates 
With 
SET 
domain 
MLL, KMT2A 
 
H3K4me1/2/3 
MLL2, KMT2D 
 
H3K4me1/2/3 
SETD1A, SET1A, 
KMT2F  
H3K4me1/2/3 
SET1D1B, SET1B, 
KMT2G  
H3K4me1/2/3 
MLL4, KMT2B 
 
H3K4me1/2/3 
MLL3, HALR, KMT2C 
 
H3K4me1/2/3 
EZH2, KTM6A, KTM6 
 
H3K27me2/3 
EZH1, KTM6B 
 
H3K27me2/3 
NSD2, WHSC1, 
MMSET  
H3K36me3 
NSD3, WHSC1L 
 
  
NSD1, KMT3B 
 
H3K36me2/3 
SET2, HYPB, SETD2 
 
H3K36me3 
ASH1L 
 
H3K4me3 
SUV39H1, KTM1A 
 
H3K9me2/3 
SUV39H2, KTM1B 
 
H3K9me2/3 
EHMT2, G9A 
 
H3K9me1/2 
EHMT1, GLP1 
 
H3K9me1/2 
SETDB1, ESET 
 
H3K9me2/3 
SETDB2, CLL8 
 
  
SETMAR 
 
  
SETD8, PR-SET7 
 
H4K20me1 
SMYD4 
 
  
MLL5, KMT2E 
 
  
SETD5 
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SETD7, SET7/9 
 
H3K4me1 
SETD4 
 
  
SUV4-20H1, KMT5B 
 
H4K20me2/3 
SUV4-20H2, KMT5C 
 
H4K20me2/3 
SMYD5 
 
  
SETD3 
 
  
SETD6 
 
  
SMYD1, KMT3D 
 
  
SMYD2, KMT3C 
 
H3K36me2 
H3K4 
SMYD3, KMT3E 
 
H3K4me2/3 
PRMD1, BLIMP1 
 
  
PRDM14 
 
  
PRDM9, MEISETZ 
 
H3K4me3 
PRDM11, PFM8 
 
  
PRDM4, PFM1 
 
  
PRDM15, PFM15 
 
  
PRDM6, PFM3 
 
  
PRDM12, PFM9 
 
  
PRDM5, PFM2 
 
  
PRDM8, PFM5 
 
  
PRDM13, PFM10 
 
  
PRDM3, PDS1-EVl1 
 
  
PRDM6, MEL1, PFM3 
 
  
PRDM2, RIZ1, KMT8 
 
H3K9 
Without 
SET 
domain 
DOT1L, KMT4 
 
H3K79 
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Table 3: Histone target substrates and domain structure of histone lysine 
demethyltransferases. 3 
  
Synonyms Protein structure Histone substrates 
Other 
substrates 
LSD 
demethylases 
LSD1, KDM1A, 
AOF2, BHC110 
 
H3K4me1, H3K4me2 p53, E2F1, 
DNMT1 H3K9me1, H3K9me2 
LSD2, KDM1B, 
AOF1  
H3K4me1, H3K4me2   
JMJC 
demethylases 
JMJD7 
 
    
HIF1AN 
 
    
HSPBAP1 
 
    
JMJD5, KDM8 
 
H3K36me2   
JMJD4 
 
    
JMJD6, PSR, 
PTDSR  
H3R2 
 
H4R3   
JMJD8 
 
    
FBXL10, 
JHDM1B, KDM2B 
 
H3K36me1, H3K36me2 
  
H3K4me3 
FBXL11, 
JHDM1A, KDM2A  
H3K36me1, H3K36me2 NFkB (p65) 
KIAA1718, 
JHDM1D  
H3K9me1, H3K9me2   
H3K27me1, H3K27me2   
PHF8, JHDM1F 
 
H3K9me1, H3K9me2   
                                                          
3 For each protein, the official name as well as the most commonly used synonyms, the 
histone target specificities and domain structure are provided. Structural domains are 
annotated. 
ARID: AT-rich interacting domain:amine oxidase: amine oxidase domain; C5HC2: C5HC2 zinc-
finger domain; CXXC: CXXC zinc-finger domain; DNMT1: DNA methyltransferase 1; FBOX: F-
box domain; FBXL: F-box and Leu-rich repeat protein; HIF1AN: hypoxia-inducible factor 1A 
inhibitor; HR: hairless domain; HSPBAP1: heat chock protein-associated protein 1; JARID: 
Jumonji domain-ARID-containing protein; JMJC: Jumonji C domain; LRR: Leu-rich repeat 
domain; LSD: Lys-specific demethylase; MINA: MYC induced nuclear antigen; NFkB: nuclear 
factor kB; NO66: nucleolar protein 66; PHD: plant homeodomain; SWIRM: Swi3p Rsc8p and 
Moira domain; TPR: tetratricopeptide domain; TUDOR: Tudor domain; UTX: ubiquitously 
transcribed X chromosome tetratricopeptide repeat protein; UTY: ubiquitously transcribed Y 
chromosome tetratricopeptide repeat protein.  
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H4K20me1   
PHF2, JHDM1E 
 
H3K9me2 ARID5B 
HR 
 
    
KDM3B 
 
    
JMJD1A, 
JHDM2A, TSGA, 
KDM3A 
 
H3K9me1, H3K9me2   
JMJD1C 
 
    
JMJD3, KDM6B 
 
H3K27me2, H3K27me3   
UTX, KDM6A 
 
H3K27me2, H3K27me3   
UTY 
 
    
JMJD2A, 
JHDM3A, KDM4A 
 
H3K9me2, H3K9me3   
H3K36me2, H3K36me3   
H1.4K26me2, H1.4K26me3   
JMJD2C, 
JHDM3C, GASC1, 
KDM4C 
 
H3K9me2, H3K9me3   
H3K36me2, H3K36me3   
H1.4K26me2, H1.4K26me3   
JMJD2B, 
JHDM3B, KDM4B  
H3K9me2, H3K9me3   
H3K36me2, H3K36me3   
H1.4K26me2, H1.4K26me3   
JMJD2D, 
JHDM3D, 
KDM4D 
 
H3K9me2, H3K9me3   
H3K36me2, H3K36me3   
H1.4K26me2, H1.4K26me3   
JARID1B, PLU1, 
KDM5B 
 
H3K4me2, H3K4me3   
JARID1C, SMCX, 
KDM5C  
H3K4me2, H3K4me3   
JARID1D, SMCY, 
KDM5D  
H3K4me2, H3K4me3   
JARID1A, RBP2, 
KDM5A  
H3K4me2, H3K4me3   
JARID2 
 
    
MINA 
 
    
NO66 
 
H3K4me2, H3K4me3   
H3K36me2, H3K36me3   
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Table 4: Association between EZH2 mutations and disease.4 
 
                                                          
4 EZH2 mutations identified in association with disease are annotated below with the 
disease-associated with each mutation, the nature of the mutation, and the structural 
domain involved. The sequence is numbered in accordance with EZH2 isoform A and the 
numbering for some mutations has been transposed from the original references so that all 
mutations can be referred to relative to the same sequence. (Abbreviations: fs, frameshift; X, 
nonsense).  
 
Mutated 
domain 
Mutation Phenotype 
CXC domain 
(503-605) 
H530N Acute myeloid leukemia 
C547fs Acute myeloid leukemia 
Q553X Acute myeloid leukemia 
C571Y Myelofibrosis 
C576W Myelodysplastic syndrome, myeloproliferative neoplasms  
P577L Early T-cell precursor acute lymphoblastic leukaemia 
R583X Chronic myelomonocytic leukemia 
SET domain 
(612-727) 
V626M Werner syndrome 
K639E Werner syndrome 
Y646N, H, F, C Diffuse large B-cell lymphoma 
I651F Early T-cell precursor acute lymphoblastic leukaemia 
V662fs Myelodysplastic syndrome 
D644E 
Atypical Chronic Myeloid Leukemia, Myelodysplastic syndrome, 
myeloproliferative neoplasms  
D664V Werner syndrome 
D664fs Acute megakaryoblastic leukemia 
N673S Chronic myelomonocytic leukemia 
L647V Myelodysplastic syndrome, Acute myeloid leukemia 
N675K Refractory Cytopenia with Multilineage Dysplasia 
V679E Myelofibrosis 
A682G Lymphoma,  
A682T Werner syndrome,  neuroblastoma 
A682V Acute myeloid leukemia 
R684C Werner syndrome, Myelofibrosis 
R684H Early T-cell precursor acute lymphoblastic leukaemia 
K685fs Chronic myelomonocytic leukemia 
R690H 
Refractory Cytopenia with Multilineage Dysplasia, Chronic 
myelomonocytic leukemia 
R690C Myelodysplastic syndrome 
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A692V Diffuse large B-cell lymphoma 
N693T Acute Myelomonocytic Leukemia 
N693Y Early T-cell precursor acute lymphoblastic leukaemia, Myelofibrosis 
H694Y Werner syndrome 
H694R Chronic myelomonocytic leukemia 
S695L 
Werner syndrome, Early T-cell precursor acute lymphoblastic 
leukaemia 
I727fs Myelodysplastic/myeloproliferative neoplasm, unclassifiable 
 
 
Other domain 
 
 
 
 
 
 
 
F728fs Early T-cell precursor acute lymphoblastic leukaemia 
Y731X Chronic myelomonocytic leukemia 
Y733fs Myelodysplastic syndrome 
Y733X Werner syndrome 
Y741C Werner syndrome 
V742ins Acute myeloid leukemia 
V742D Early T-cell precursor acute lymphoblastic leukaemia 
I744fs Acute myeloid leukemia 
E745K Werner syndrome, lymphoma 
E745fs Acute myeloid leukemia 
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Table 5: Chemical structures and biochemical data for small-molecule inhibitors of EZH2  
Structure Compount 
Mechanism 
and potency 
Selectivity 
toward EZH2 
Highest 
clinical 
status 
Reférences 
 
DZNep 
SAH 
hydrolase 
inhibitor 
non selective preclinical 
[79,131–
134] 
 
GSK126 
SAM-
competive 
inhibitor of 
PRC2,  
Ki = 0,5-3 nM 
> 1000-fold over 
20 other HMTs; 
over EZH1 
preclinical [99,135] 
 
GSK343 
SAM-
competive 
inhibitor of 
PRC2,  
Ki = 0,5-3 nM 
IC50 = 4nM and 
is over 1000-fold 
selective for 
other HMTs 
except EZH1 (60-
fold selectivity) 
preclinical [136,137] 
 
 
EPZ005687 
SAM-
competive 
inhibitor of 
PRC2, 
 Ki = 24 nM 
> 500-fold over 
15 other HMTs; 
about 50-fold 
over EZH1 
preclinical [138] 
 
 
EPZ-6438 
SAM-
competive 
inhibitor of 
PRC2, 
 Ki = 0,5-3 nM 
IC50 = 11 nM 
35-fold 
selectivity versus 
EZH1 ; >4,500-
fold selectivity 
relative to 14 
other HMTs 
phase I/II [139] 
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El1 
SAM-
competitive 
inhibitor of 
PRC2  
IC50=15 nM; 
Ki=13 nM 
 
preclinical [140] 
 
UNC1999 
SAM-
competitive 
inhibitor of 
PRC2  
IC50=2-15 
nM; Ki=13 
nM  
  
over 1000-fold 
selective for 
other HMTs 
except EZH1 (22-
fold selectivity). 
preclinical [141] 
Peptide: 
FSSNRXKILXRTQILNQEWKQRRIQPV 
stabilized 
a-helix of 
EZH2 
peptide 
(SAH-
EZH2) 
Hydrocarbon-
stapled 
peptide that 
mimics the a-
helical EED-
dinding 
domain of 
EZH2, 
disrupting 
the EZH2–
EED complex 
not selective for 
EZH1 
preclinical [142] 
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Table 1: List of histone lysine methyltransferases and demethylases linked to disease.1 2 
  
Gene 
histone 
substrate 
Disease 
Genetic/epigenetic 
aberration 
Aberrant 
expression 
References 
h
is
to
n
e 
ly
si
n
e 
m
et
h
yl
 t
ra
n
sf
er
as
e
 
MLL H3K4 
Leukemia (AML, ALL, MLL) 
> 50 different MLL 
fusions 
  [1–7] 
Acute myeloid leukemia (AML) MLL-PTD   [8–10] 
Wiedemann-Steiner syndrome intragenic mutations   [11–13] 
MLL2 H3K4 
Hepatocellular carninoma (HCC) 
Hepatitis B virus 
integration into MLL2 : 
HBx-MLL2 fusion 
  [14] 
Acute myeloid leukemia (AML) 
(mice) 
NUP98-JARID1A   [15] 
Kabuki syndrome 1 (KABUK1) intragenic mutations   [16,17] 
MLL3 H3K4 
Leukemia     [18,19] 
Colorectal cancer Intragenic mutations   [19–22] 
DOT1L H3K79 
Leukemia (AML, ALL) 
MLL-AF10 fusion, MLL-
AF4 fusion 
  [23,24] 
T cell acute lymphoblastic 
leukemia (T-ALL) 
CALM-AF10 fusion, SET-
NUP214 fusion 
  [25,26] 
Osteoarthritis intragenic mutations   [27,28] 
EZH2 H3K27 
Bladder carcinoma   overexpression [29–36] 
Breast cancer   overexpression [29,30,37,38] 
Colorectal cancer    overexpression [29,39–45] 
Gastric cancer    overexpression [46–53] 
Hepatocellular carcinoma   overexpression [54–59] 
Lymphoma Intragenic mutations 
overexpression 
downregulation 
[60–82] 
[64] 
Myeloproliferative neoplasms Intragenic mutations 
 
[83–91] 
Rhabdoid tumors 
Intragenic mutations; 
Mutations of opposing 
chromatin modifying 
complex SWI-SNF 
 
[92–94] 
 
[95] 
Melanoma   overexpression [38,96–99] 
Prostate cancer   overexpression [100–121] 
chondrosarcoma 
 
overexpression [122] 
lung cancer 
 
downregulation [123] 
Various other cancers   overexpression [29,38] 
Weaver syndrome Intragenic mutations   [124–126] 
                                                          
1 However, in many cases the molecular mechanisms of disease development are not well 
understood yet, and it remains to be shown whether misregulation of these HMTs 
contributes to disease initiation or progression. 
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NSD1 H3K36 
Acute myeloid leukemia (AML) 
t(5;11)(q32;p15,5); 
tranlocation: NUP98-
NSD1 fusion 
  [127–138]  
Myelodysplastic syndrome t(5,11)(q35;p15,5)   [131,139] 
Beckwith-Wiedemann syndrome intragenic mutations   [140] 
Sotos syndrome 
intragenic mutations; 
5q35 microdeletions 
  [140–173] 
NSD2 H3K36 
glioblastoma multiform (GBM)   overexpression [174] 
hepatocellular carcinoma (HCC)   overexpression [175] 
leukemia   overexpression [176] 
multiple myeloma (MM) 
t(4;14)(p16;q32): altered 
expression of FGFR3, 
NSD2 
  [177,178] 
Various other cancers     [179] 
Wolf-Hirschhorn syndrome     [180] 
NSD3   acute myeloid leukemia (AML) 
t(8;11)(p11,2;p15); 
translocation: NUP98-
NSD3 fusion 
  [181] 
EHMT1 H3K9 
9q subtelomeric deletion 
syndrome / Kleefstra syndrome 
haploinsufficiency of 
EHMT1; microdeletion 
of 9q34.3: intragenic 
mutation 
downregulation [175,182–185] 
breast cancer intragenic mutations   [186] 
medulloblastoma   downregulation [187] 
SETDB1 H3K9 Huntington's disease (HD)   overexpression [188] 
SETDB2   asthma mutation   [189] 
SMYD2 
H3K4 
H3K36 
pediatric acute lymphoblastic 
leukemia 
  overexpression [190] 
esophageal squamous cell 
carcinoma 
  overexpression [191] 
hepatocellular carcinoma (HCC)   overexpression [192]  
SMYD3 H3K4 
breast cancer   overexpression [193,194] 
colorectal cancer   overexpression [195] 
hepatocellular carcinoma (HCC)   overexpression [196] 
SMYD4   
breast cancer   downregulation [197] 
medulloblastoma   downregulation [187] 
PRDM1   
lymphoma 
mutations in PRDM1 
gene, epigenetic 
silencing 
  [198–207] 
lupus erythematosus   overexpression [208–210] 
Crohn's disease intragenic mutation   [211–213] 
PRDM2 H3K9 
breast cancer 
mutations in PRDM2 
gene; promoter DNA 
methylation 
  [186,214,215] 
colorectal cancer (CRC) 
mutations in PRDM2 
gene 
  [216–218] 
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gastric cancer  
mutations in PRDM2 
genes, promoter DNA 
methylation 
  [216,218–221] 
hepatocellular carcinoma (HCC) 
promoter DNA 
methylation 
downregulation [222–226] 
lung cancer   downregulation [215,227] 
neuroblastoma   downregulation [228,229] 
PRDM5   
breast cancer 
promoter DNA 
methylation 
downregulation [230] 
colorectal and gastric cancer 
promoter DNA 
methylation 
downregulation [231] 
liver cancer 
promoter DNA 
methylation 
downregulation [230] 
PRDM8   lafora disease mutation   [232] 
PRDM9 H3K4 azoospermia, infertility mutation   [233–235] 
PRDM12   chronic myeloid leukemia (CML) 
9q microdeletions 
encompassing RRP4 and 
PRDM12 
  [236] 
PRDM14   breast cancer   overexpression [237] 
H
is
to
n
e 
d
em
e
th
yl
as
e 
LSD1 
H3K4 
H3K9 
neuroblastoma   overexpression [238] 
chondrosarcoma, Ewing's 
sarcoma, osteosarcoma   
overexpression [239] 
leukemia   overexpression [238,240–243] 
others cancers   overexpression [238,244–263] 
hypertension   downregulation [264,265] 
JMJD5 H3K36 tumors   overexpression [266] 
KDM2B 
H3K36 
H3K4 
leukemias 
  
overexpression [267] 
PHF8 
H3K9 
H4K20 
 X-linked mental retardation mutation 
  
[268–272] 
JMJD1A H3K9 
Ewing sarcoma   overexpression [273] 
kidney cancer   overexpression [274] 
JMJD3 H3K27 
hodgkin's lymphoma   overexpression [275] 
renal cell carcinoma   overexpression [276] 
UTX H3K27  
Kabuki syndrome mutation   [277–280] 
cancers mutation   [276,281–293] 
JMJD2A 
H3K9 
H3K36 
H1.4K26 
cancers   overexpression [258,294–300] 
JMJD2C 
H3K9 
H3K36 
H1.4K26 
cancers   overexpression [301–304] 
JMJD2B 
H3K9 
H3K36 
H1.4K26 
cancers   overexpression [305–310] 
KDM5B H3K4 melanoma   overexpression [311–315] 
 47 
 
prostate cancer   overexpression [316] 
breast cancer   overexpression [317–322]  
KDM5C H3K4 
non-syndromic X-linked mental 
retardation 
mutation   [323–333] 
KDM5A H3K4 breast cancer   overexpression [334] 
 3 
 4 
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